FAP and gastric cancer: In vivo models of colorectal cancer also indicate that colorectal cancer cell lines co-injected with FAP+ CAFs have increased resistance to anti-PD-1 treatment (78), while in vivo models of gastric cancer revealed that anti-PD-1 treatment and FAP inhibitors have a synergistic effect in terms of slowing tumor growth (64).